BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. J Exp Pharmacol 2021;13:303-28. [PMID: 33776489 DOI: 10.2147/JEP.S267383] [Cited by in Crossref: 51] [Cited by in F6Publishing: 58] [Article Influence: 25.5] [Reference Citation Analysis]
Number Citing Articles
1 Dong XQ, Chu LK, Cao X, Xiong QW, Mao YM, Chen CH, Bi YL, Liu J, Yan XM. Glutathione metabolism rewiring protects renal tubule cells against cisplatin-induced apoptosis and ferroptosis. Redox Rep 2023;28:2152607. [PMID: 36692085 DOI: 10.1080/13510002.2022.2152607] [Reference Citation Analysis]
2 Shpilt Z, Melamed-Book N, Tshuva EY. An anticancer Ti(IV) complex increases mitochondrial reactive oxygen species levels in relation with hypoxia and endoplasmic-reticulum stress: A distinct non DNA-related mechanism. J Inorg Biochem 2023;243:112197. [PMID: 36963201 DOI: 10.1016/j.jinorgbio.2023.112197] [Reference Citation Analysis]
3 Yao J, Liu L, Sun Q, Shen X. Direct cellular targets and anticancer mechanisms of the natural product oridonin. MedComm – Future Medicine 2023;2. [DOI: 10.1002/mef2.35] [Reference Citation Analysis]
4 Arabi A, Cogley MO, Fabrizio D, Stitz S, Howard WA, Wheeler KA. Anticancer Activity of Nonpolar Pt(CH(3))(2)I(2){bipy} is Found to be Superior among Four Similar Organoplatinum(IV) Complexes. J Mol Struct 2023;1274:134551. [PMID: 36644319 DOI: 10.1016/j.molstruc.2022.134551] [Reference Citation Analysis]
5 Awwad SW, Serrano-Benitez A, Thomas JC, Gupta V, Jackson SP. Revolutionizing DNA repair research and cancer therapy with CRISPR-Cas screens. Nat Rev Mol Cell Biol 2023. [PMID: 36781955 DOI: 10.1038/s41580-022-00571-x] [Reference Citation Analysis]
6 Sidhu H, Capalash N. Plumbagin downregulates UHRF1, p-Akt, MMP-2 and suppresses survival, growth and migration of cervical cancer CaSki cells. Toxicol In Vitro 2023;86:105512. [PMID: 36336213 DOI: 10.1016/j.tiv.2022.105512] [Reference Citation Analysis]
7 Ooi TC, Nordin FJ, Rahmat NS, Abdul Halim SN', Sarip R, Chan KM, Rajab NF. Genotoxicity and apoptotic effect of silver(I) complexes with mixed-ligands of thiosemicarbazones and diphenyl(p-tolyl)phosphine on malignant melanoma cells, SK-MEL-28. Mutat Res Genet Toxicol Environ Mutagen 2023;886:503581. [PMID: 36868695 DOI: 10.1016/j.mrgentox.2022.503581] [Reference Citation Analysis]
8 Chang MR, Rusanov DA, Arakelyan J, Alshehri M, Asaturova AV, Kireeva GS, Babak MV, Ang WH. Targeting emerging cancer hallmarks by transition metal complexes: Cancer stem cells and tumor microbiome. Part I. Coordination Chemistry Reviews 2023;477:214923. [DOI: 10.1016/j.ccr.2022.214923] [Reference Citation Analysis]
9 Kralj J, Pernar Kovač M, Dabelić S, Polančec DS, Wachtmeister T, Köhrer K, Brozovic A. Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT. Br J Cancer 2023. [PMID: 36717670 DOI: 10.1038/s41416-023-02140-1] [Reference Citation Analysis]
10 Coleman KL, Chiaramonti M, Haddad B, Ranzenberger R, Henning H, Al Khashali H, Ray R, Darweesh B, Guthrie J, Heyl D, Evans HG. Phosphorylation of IGFBP-3 by Casein Kinase 2 Blocks Its Interaction with Hyaluronan, Enabling HA-CD44 Signaling Leading to Increased NSCLC Cell Survival and Cisplatin Resistance. Cells 2023;12. [PMID: 36766747 DOI: 10.3390/cells12030405] [Reference Citation Analysis]
11 Özerkan D. The Determination of Cisplatin and Luteolin Synergistic Effect on Colorectal Cancer Cell Apoptosis and Mitochondrial Dysfunction by Fluorescence Labelling. J Fluoresc 2023. [PMID: 36652047 DOI: 10.1007/s10895-023-03145-y] [Reference Citation Analysis]
12 Azizidoost S, Ghaedrahmati F, Sheykhi-Sabzehpoush M, Uddin S, Ghafourian M, Mousavi Salehi A, Keivan M, Cheraghzadeh M, Nazeri Z, Farzaneh M, Khoshnam SE. The role of LncRNA MCM3AP-AS1 in human cancer. Clin Transl Oncol 2023;25:33-47. [PMID: 36002764 DOI: 10.1007/s12094-022-02904-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Wang G, Ouyang B, Jing F, Dai X. GBA inhibition suppresses ovarian cancer growth, survival and receptor tyrosine kinase AXL-mediated signaling pathways. Korean J Physiol Pharmacol 2023;27:21-9. [PMID: 36575930 DOI: 10.4196/kjpp.2023.27.1.21] [Reference Citation Analysis]
14 Poodat M, Divsalar A, Ghalandari B, Khavarinezhad R. A new nano-delivery system for cisplatin using green-synthesized iron oxide nanoparticles. J IRAN CHEM SOC 2022. [DOI: 10.1007/s13738-022-02706-5] [Reference Citation Analysis]
15 Geohagen B, Zeldin E, Reidy K, Wang T, Gavathiotis E, Fishman YI, LoPachin R, Loeb DM, Weiser DA. Acetophenone protection against cisplatin-induced end-organ damage. Transl Oncol 2022;27:101595. [PMID: 36477009 DOI: 10.1016/j.tranon.2022.101595] [Reference Citation Analysis]
16 Corti A, Dominici S, Piaggi S, Pompella A. Enhancement of ferroptosis by boric acid and its potential use as chemosensitizer in anticancer chemotherapy. BioFactors 2022. [DOI: 10.1002/biof.1919] [Reference Citation Analysis]
17 Granit A, Mishra K, Barasch D, Peretz-Yablonsky T, Eyal S, Kakhlon O. Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin. Front Cell Dev Biol 2022;10:1014798. [PMID: 36544904 DOI: 10.3389/fcell.2022.1014798] [Reference Citation Analysis]
18 Gao J, Li Y, Zou X, Lei T, Xu T, Chen Y, Wang Z. HEY1-mediated cisplatin resistance in lung adenocarcinoma via epithelial-mesenchymal transition. Med Oncol 2022;40:18. [PMID: 36396748 DOI: 10.1007/s12032-022-01886-7] [Reference Citation Analysis]
19 Liu Q, Li X, Luo Y, Wang H, Zhang Y, Yu T. Ultrasonically Enhanced ZD2767P–Carboxypeptidase G2 Deactivates Cisplatin-Resistant Human Lung Cancer Cells. Oxidative Medicine and Cellular Longevity 2022;2022:1-14. [DOI: 10.1155/2022/9191233] [Reference Citation Analysis]
20 Zanetti RD, da Cunha GA, Moreira MB, Farias RL, de Souza RF, de Godoy PR, Brassesco MS, Rocha FV, Lima MA, Mauro AE, Netto AV. Orthopalladated N,N-Dimethyl-1-Phenethylamine Compounds Containing 2,6-Lutidine: Synthesis, Dna Binding Studies and Cytotoxicity Evaluation. Polyhedron 2022. [DOI: 10.1016/j.poly.2022.116185] [Reference Citation Analysis]
21 Seneme EF, Dos Santos DC, de Lima CA, Zelioli ÍAM, Sciani JM, Longato GB. Effects of Myristicin in Association with Chemotherapies on the Reversal of the Multidrug Resistance (MDR) Mechanism in Cancer. Pharmaceuticals (Basel) 2022;15. [PMID: 36297344 DOI: 10.3390/ph15101233] [Reference Citation Analysis]
22 Buyana B, Naki T, Alven S, Aderibigbe BA. Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy. IJMS 2022;23:11261. [DOI: 10.3390/ijms231911261] [Reference Citation Analysis]
23 Yuan Y, Zhang X, Fan X, Peng Y, Jin Z. The emerging roles of circular RNA-mediated autophagy in tumorigenesis and cancer progression. Cell Death Discov 2022;8. [DOI: 10.1038/s41420-022-01172-5] [Reference Citation Analysis]
24 Kouba S, Hague F, Ahidouch A, Ouadid-ahidouch H. Crosstalk between Ca2+ Signaling and Cancer Stemness: The Link to Cisplatin Resistance. IJMS 2022;23:10687. [DOI: 10.3390/ijms231810687] [Reference Citation Analysis]
25 Sala L, Perecko T, Mestek O, Pinkas D, Homola T, Kočišek J. Cisplatin-Cross-Linked DNA Origami Nanostructures for Drug Delivery Applications. ACS Appl Nano Mater . [DOI: 10.1021/acsanm.2c02976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lin C, Lin C, Wu J, Tsai H, Cheng S, Liao H, Lin T, Wu C, Lin Y, Wang J, Chang G. Effects of Para-Toluenesulfonamide on Canine Melanoma Xenotransplants in a BALB/c Nude Mouse Model. Animals 2022;12:2272. [DOI: 10.3390/ani12172272] [Reference Citation Analysis]
27 Ajibare AC, Ebuehi OAT, Adisa RA, Sofidiya MO, Olugbuyiro JA, Akinyede KA, Iyiola HA, Adegoke YA, Omoruyi SI, Ekpo OE. Fractions of Hoslundia opposita Vahl and hoslundin induced apoptosis in human cancer cells via mitochondrial-dependent reactive oxygen species (ROS) generation. Biomedicine & Pharmacotherapy 2022;153:113475. [DOI: 10.1016/j.biopha.2022.113475] [Reference Citation Analysis]
28 Ranasinghe R, Mathai ML, Zulli A. Cisplatin for cancer therapy and overcoming chemoresistance. Heliyon 2022;8:e10608. [PMID: 36158077 DOI: 10.1016/j.heliyon.2022.e10608] [Reference Citation Analysis]
29 Zheng H, Liu Q, Wang S, Liu X, Ma M, Shen T, Wang X, Ren D. Epimedokoreanin B inhibits the growth of lung cancer cells through endoplasmic reticulum stress-mediated paraptosis accompanied by autophagosome accumulation. Chem Biol Interact 2022;:110125. [PMID: 36027945 DOI: 10.1016/j.cbi.2022.110125] [Reference Citation Analysis]
30 Mukherjee N, Browne A, Ivers L, Santra T, Cremona M, Hennessy BT, O’donovan N, Crown J, Kolch W, Fey D, Eustace AJ. A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin. JPM 2022;12:1277. [DOI: 10.3390/jpm12081277] [Reference Citation Analysis]
31 Xu X, Jaberi-douraki M, Wallace NA. Predicting the Prognostic Value of POLI Expression in Different Cancers via a Machine Learning Approach. IJMS 2022;23:8571. [DOI: 10.3390/ijms23158571] [Reference Citation Analysis]
32 Krasowska D, Gerkowicz A, Wróblewska-Łuczka P, Grabarska A, Załuska-Ogryzek K, Krasowska D, Łuszczki JJ. Anticancer Activity of Amantadine and Evaluation of Its Interactions with Selected Cytostatics in Relation to Human Melanoma Cells. Int J Mol Sci 2022;23. [PMID: 35886997 DOI: 10.3390/ijms23147653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Rawat SG, Tiwari RK, Jaiswara PK, Gupta VK, Sonker P, Vishvakarma NK, Kumar S, Pathak C, Gautam V, Kumar A. Phosphodiesterase 5 inhibitor sildenafil potentiates the antitumor activity of cisplatin by ROS-mediated apoptosis: a role of deregulated glucose metabolism. Apoptosis 2022. [PMID: 35725975 DOI: 10.1007/s10495-022-01741-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Liu S, Wen X, Huang Q, Zhu M, Lu J. Selenium Status in Diet Affects Nephrotoxicity Induced by Cisplatin in Mice. Antioxidants (Basel) 2022;11:1141. [PMID: 35740039 DOI: 10.3390/antiox11061141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Pompella A, Corti A, Visvikis A. Redox Mechanisms in Cisplatin Resistance of Cancer Cells: The Twofold Role of Gamma-Glutamyltransferase 1 (GGT1). Front Oncol 2022;12:920316. [DOI: 10.3389/fonc.2022.920316] [Reference Citation Analysis]
36 Bontemps I, Lallemand C, Biard D, Dechamps N, Kortulewski T, Bourneuf E, Siberchicot C, Boussin F, Chevillard S, Campalans A, Lebeau J. Loss of CD24 promotes radiation- and chemo-resistance by inducing stemness properties associated with a hybrid E/M state in breast cancer cells.. [DOI: 10.1101/2022.05.05.490732] [Reference Citation Analysis]
37 Ferraro MG, Piccolo M, Misso G, Santamaria R, Irace C. Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics. Pharmaceutics 2022;14:954. [DOI: 10.3390/pharmaceutics14050954] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
38 Abdel-Latif R, Fathy M, Anwar HA, Naseem M, Dandekar T, Othman EM. Cisplatin-Induced Reproductive Toxicity and Oxidative Stress: Ameliorative Effect of Kinetin. Antioxidants (Basel) 2022;11:863. [PMID: 35624727 DOI: 10.3390/antiox11050863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
39 Luo Y, Yu T, Li X, Qian G. Thioridazine Enhances Cisplatin-Induced DNA Damage in Cisplatin-Resistant Human Lung Cancer Cells. Evid Based Complement Alternat Med 2022;2022:3702665. [PMID: 35399625 DOI: 10.1155/2022/3702665] [Reference Citation Analysis]
40 Kan T, Lin M, Cheng C, Lu J, Sheu M, Ho Y, Rahayu S, Chang J. Preclinical Therapeutic Assessment of a New Chemotherapeutics [Dichloro(4,4’-Bis(2,2,3,3-Tetrafluoropropoxy) Methyl)-2,2’-Bipryridine) Platinum] in an Orthotopic Patient-Derived Xenograft Model of Triple-Negative Breast Cancers. Pharmaceutics 2022;14:839. [DOI: 10.3390/pharmaceutics14040839] [Reference Citation Analysis]
41 Tsvetkova D, Ivanova S. Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases. Molecules 2022;27:2466. [PMID: 35458666 DOI: 10.3390/molecules27082466] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
42 Maiuolo J, Musolino V, Gliozzi M, Carresi C, Oppedisano F, Nucera S, Scarano F, Scicchitano M, Guarnieri L, Bosco F, Macrì R, Ruga S, Cardamone A, Coppoletta AR, Ilari S, Mollace A, Muscoli C, Cognetti F, Mollace V. The Employment of Genera Vaccinium, Citrus, Olea, and Cynara Polyphenols for the Reduction of Selected Anti-Cancer Drug Side Effects. Nutrients 2022;14:1574. [DOI: 10.3390/nu14081574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Henzi T, Diep K, Oberson A, Salicio V, Bochet CG, Schwaller B. Forchlorfenuron and Novel Analogs Cause Cytotoxic Effects in Untreated and Cisplatin-Resistant Malignant Mesothelioma-Derived Cells. IJMS 2022;23:3963. [DOI: 10.3390/ijms23073963] [Reference Citation Analysis]
44 Yoon J, Kim H, Jeong YI, Yang HS. CD44 Receptor-Mediated/Reactive Oxygen Species-Sensitive Delivery of Nanophotosensitizers against Cervical Cancer Cells. Int J Mol Sci 2022;23:3594. [PMID: 35408970 DOI: 10.3390/ijms23073594] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Xu J, Gewirtz DA. Is Autophagy Always a Barrier to Cisplatin Therapy? Biomolecules 2022;12:463. [DOI: 10.3390/biom12030463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Ma W, Yin S, Chen J, Geng X, Liu M, Li H, Liu M, Liu H. Stimulating the Hematopoietic Effect of Simulated Digestive Product of Fucoidan from Sargassum fusiforme on Cyclophosphamide-Induced Hematopoietic Damage in Mice and Its Protective Mechanisms Based on Serum Lipidomics. Marine Drugs 2022;20:201. [DOI: 10.3390/md20030201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Tian C, Wei Y, Li J, Huang Z, Wang Q, Lin Y, Lv X, Chen Y, Fan Y, Sun P, Xiang R, Chang A, Yang S. A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer. Int J Mol Sci 2022;23:2892. [PMID: 35270034 DOI: 10.3390/ijms23052892] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Yang Z, Liao J, Lapidus RG, Fan X, Mehra R, Cullen KJ, Dan H. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma. Cancer Chemother Pharmacol 2022. [PMID: 35212780 DOI: 10.1007/s00280-022-04410-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Li T, Tang Z, Li C, Liu X, Cheng L, Yang Z, Zhu X, Liu W, Huang Y. Magnesium-Assisted Cisplatin Inhibits Bladder Cancer Cell Survival by Modulating Wnt/β-Catenin Signaling Pathway. Front Pharmacol 2021;12:804615. [PMID: 35153759 DOI: 10.3389/fphar.2021.804615] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Lash LH. Unexpected Enhancement of Cytotoxicity of Cisplatin in a Rat Kidney Proximal Tubular Cell Line Overexpressing Mitochondrial Glutathione Transport Activity. Int J Mol Sci 2022;23:1993. [PMID: 35216119 DOI: 10.3390/ijms23041993] [Reference Citation Analysis]
51 Koritala BSC, Porter KI, Sarkar S, Gaddameedhi S. Circadian disruption and cisplatin chronotherapy for mammary carcinoma. Toxicol Appl Pharmacol 2022;436:115863. [PMID: 34998857 DOI: 10.1016/j.taap.2022.115863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Chen J, Wu S, Wang J, Sha Y, Ji Y. Hsa_circ_0074269-mediated Upregulation of TUFT1 Through miR-485-5p Increases Cisplatin Resistance in Cervical Cancer. Reprod Sci 2022. [PMID: 35075616 DOI: 10.1007/s43032-022-00855-9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
53 Chi M, Zhang H, Wang Y, Sun X, Yang Q, Guo C, Sakuma K. Silibinin Alleviates Muscle Atrophy Caused by Oxidative Stress Induced by Cisplatin through ERK/FoxO and JNK/FoxO Pathways. Oxidative Medicine and Cellular Longevity 2022;2022:1-22. [DOI: 10.1155/2022/5694223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Rothzerg E, Pfaff AL, Koks S. Innovative approaches for treatment of osteosarcoma. Exp Biol Med (Maywood). [DOI: 10.1177/15353702211067718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
55 Rutz J, Maxeiner S, Juengel E, Chun FK, Tsaur I, Blaheta RA. Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway. Nutrients 2022;14:369. [PMID: 35057550 DOI: 10.3390/nu14020369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Othman MS, Obeidat ST, Al-Bagawi AH, Fareid MA, Fehaid A, Abdel Moneim AE. Green-synthetized selenium nanoparticles using berberine as a promising anticancer agent. J Integr Med 2022;20:65-72. [PMID: 34802980 DOI: 10.1016/j.joim.2021.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
57 Wang S, Tsai K, Chou W, Cheng H, Huang Y, Ou H, Chang Y. Quercetin Mitigates Cisplatin-Induced Oxidative Damage and Apoptosis in Cardiomyocytes through Nrf2/HO-1 Signaling Pathway. Am J Chin Med 2022;50:1281-1298. [DOI: 10.1142/s0192415x22500537] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Chen C, Xie D, Gewirtz DA, Li N. Nephrotoxicity in cancer treatment: An update. Advances in Cancer Research 2022. [DOI: 10.1016/bs.acr.2022.03.005] [Reference Citation Analysis]
59 Chang C, Lee C, Lee G, Lu K. The straightforward synthesis of N-coordinated ruthenium 4-aryl-1,2,3-triazolato complexes by [3 + 2] cycloaddition reactions of a ruthenium azido complex with terminal phenylacetylenes and non-covalent aromatic interactions in structures. RSC Adv 2022;12:24830-8. [DOI: 10.1039/d2ra04835c] [Reference Citation Analysis]
60 El-Sheikh A, Khired Z. Interactions of Analgesics with Cisplatin: Modulation of Anticancer Efficacy and Potential Organ Toxicity. Medicina (Kaunas) 2021;58:46. [PMID: 35056355 DOI: 10.3390/medicina58010046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
61 Nurcahyanti ADR, Kusmita L, Wink M. Bixin and fucoxanthin sensitize human lung cancer and cervical cancer cell to cisplatin in vitro. BMC Res Notes 2021;14:454. [PMID: 34922615 DOI: 10.1186/s13104-021-05866-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Zhu H, Loh XJ, Ye E, Li Z. Polymeric Matrix-Based Nanoplatforms toward Tumor Therapy and Diagnosis. ACS Materials Lett 2022;4:21-48. [DOI: 10.1021/acsmaterialslett.1c00558] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
63 Sekino Y, Pham QT, Kobatake K, Kitano H, Ikeda K, Goto K, Hayashi T, Nakahara H, Sentani K, Oue N, Yasui W, Teishima J, Hinata N. KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer. J Clin Med 2021;10:4837. [PMID: 34768355 DOI: 10.3390/jcm10214837] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Niu Z, Li X, Dong S, Gao J, Huang Q, Yang H, Qian H, Zhuo S, Zhuang T, Zhu J, Ding Y, Xu W. The E3 Ubiquitin Ligase HOIP inhibits Cancer Cell Apoptosis via modulating PTEN stability. J Cancer 2021;12:6553-62. [PMID: 34659546 DOI: 10.7150/jca.61996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Domínguez-Jurado E, Cimas FJ, Castro-Osma JA, Juan A, Lara-Sánchez A, Rodríguez-Diéguez A, Shafir A, Ocaña A, Alonso-Moreno C. Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer. Pharmaceutics 2021;13:1559. [PMID: 34683852 DOI: 10.3390/pharmaceutics13101559] [Reference Citation Analysis]
66 Petersen I. Classification and Treatment of Diseases in the Age of Genome Medicine Based on Pathway Pathology. Int J Mol Sci 2021;22:9418. [PMID: 34502326 DOI: 10.3390/ijms22179418] [Reference Citation Analysis]
67 Umfress A, Speed HE, Tan C, Ramezani S, Birnbaum S, Brekken RA, Sun X, Plattner F, Powell CM, Bibb JA. Neuropathological Effects of Chemotherapeutic Drugs. ACS Chem Neurosci 2021;12:3038-48. [PMID: 34370453 DOI: 10.1021/acschemneuro.1c00338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
68 Rodriguez E, Pei G, Kim ST, German A, Robinson P. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers (Basel) 2021;13:3871. [PMID: 34359773 DOI: 10.3390/cancers13153871] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
69 Shu Y, Lin J, Zhu B, Liu Q, Zhou B, Hu H, Ju D. Synthesis and Antitumor Activity of (3-Hydroxyacrylato-O,O′) Diammineplatinum(II). Pharmaceutical Fronts 2021;03:e13-7. [DOI: 10.1055/s-0041-1730956] [Reference Citation Analysis]
70 van Harten AM, Brakenhoff RH. Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications. Cancers (Basel) 2021;13:2774. [PMID: 34204886 DOI: 10.3390/cancers13112774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]